Back to search

Germany· DE-A57-4950b8764ae59d11

Eslicarbazepin Aristo

A eslicarbazepine product containing eslicarbazepine acetate, registered in Germany by Aristo Pharma Gmbh (Art 57). The same ATC class is registered in 16 of our 19 countries.

ATC N03AF04

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedEslicarbazepin AristoATCN03AF04REGISTER NO.DE-A57-4950b8764ae59d…PACKS LISTED0CHECKEDSeptember 30, 2026

Where it is registered

Eslicarbazepine is registered in 16 of 19 countries.

Countries holding a registration under ATC N03AF04 (eslicarbazepine), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 10 of them publish a price we can compare per daily dose

Eslicarbazepine · ATC N03AF04

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of eslicarbazepine costs, country by country.

Normalised to the WHO defined daily dose (0.8 g), the median price runs from $2.32 in Italy to $4.08 in Switzerland — a ×1.8 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Eslicarbazepine · price per daily dose (0.8 g)

USD · FX 28 Sept 2026

  • CH Switzerland$4.08
  • ES Spain$3.49
  • IT Italy$2.32
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

EMA Article 57 (European Union)
Active substance
Eslicarbazepine Acetate
Manufacturer
Aristo Pharma Gmbh (Art 57)
Country
Germany (DE)
ATC code
N03AF04
ATC class
Eslicarbazepine
Defined daily dose
0.8 g, O
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

188 interactions on record for eslicarbazepine.

Graded by severity as the source publishes them — 17 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Eslicarbazepine · interactions on record

188 records

  • 17 severe
  • 166 moderate
  • 5 minor

Most severe, free to view

  • Levonorgestrel and ethinylestradiolG03AA07severe
  • Desogestrel and ethinylestradiolG03AA09severe
  • Drospirenone and ethinylestradiolG03AA12severe
  • EthinylestradiolG03CA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Eslicarbazepine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All eslicarbazepine products

Authorised across Europe · EMA

The same active substance is authorised in 20 EEA countries. Names it is sold under:

  • Austria · Eslibon
  • Bulgaria · Еслибон
  • Cyprus · Esran
  • Czechia · Eslibon, Eslikarbazepin Neuraxpharm
  • Denmark · Arupsan, Eslicarbazepinacetat "stada"
  • Spain · Arupsan, Bixcar
  • France · Eslicarbazepine 800, Eslicarbazepine Arrow
  • United Kingdom (Northern Ireland) · Arupsan, Eslicarbazepine Amarox
  • Greece · Esran
  • Hungary · Eslicarbazepine 800
  • Iceland · Eslicarbazepin, Eslicarbazepine Acetate Stada
  • Italy · Arupsan, Eslicarbazepina Acetato Aurobindo
  • Liechtenstein · Zebinix
  • Malta · Esran
  • Netherlands · Eslibon
  • Norway · Zebinix
  • Poland · Eslibon
  • Portugal · Acetato De Eslicarbazepina Alter, Acetato De Eslicarbazepina Aristo
  • Sweden · Arupsan
  • Slovakia · Eslibon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/15c8ba67-cc80-4bb8-b770-383ca8c0766e
GET /v1/drugs/15c8ba67-cc80-4bb8-b770-383ca8c0766e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Oral Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Eslicarbazepine Acetate",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}

See everything about eslicarbazepine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.